Verastem (VSTM)
Markets AVMAPKI FAKZYNJA and develops small-molecule drugs for RAS/MAPK-driven cancers.
$8.37
vs last close+0.38 (+4.78%)
Something off on this page? Send us feedback.
Next report
Nov 3, 26
in 42 days
EPS estimate
−$0.44
Revenue estimate
$29.3M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.33−$0.96−$0.39−$1.35−$0.39−$0.37−$0.35Pending
Estimate−$0.81−$0.72−$0.85−$0.51−$0.49−$0.46−$0.43−$0.44
Surprise−64.2%−33.3%+54.1%−164.7%+20.4%+19.6%+18.7%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$10.0M—$2.1M$11.2M$17.5M$18.7M$40.1MPending
Estimate$150.0K$100.0K$5.7M$16.5M$16.9M$21.4M$22.9M$29.3M
Surprise+6,550.7%—−62.5%−32.0%+3.7%−12.9%+75.2%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.65 | — | — |
| Sep 2027 | −$0.62 | — | — |
| Jun 2027 | −$0.61 | — | — |
| Mar 2027 | −$0.59 | — | — |
| Dec 2026 | −$0.38 | — | — |
| Nov 2026 | −$0.44 | — | — |
| Aug 2026 | −$0.43 | −$0.35 | +18.7% |
| May 2026 | −$0.46 | −$0.37 | +19.6% |
| Mar 2026 | −$0.49 | −$0.39 | +20.4% |
| Nov 2025 | −$0.51 | −$1.35 | −164.7% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Oct 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.65 | — | — | $49.4M | — | — | — |
| Sep 2027 | −$0.62 | — | — | $46.0M | — | — | — |
| Jun 2027 | −$0.61 | — | — | $41.7M | — | — | — |
| Mar 2027 | −$0.59 | — | — | $38.8M | — | — | — |
| Dec 2026 | −$0.38 | — | — | $34.6M | — | — | — |
| Nov 3, 2026 | −$0.44 | — | — | $29.3M | — | — | — |
| Aug 6, 2026 | −$0.43 | −$0.35 | +18.7% | $22.9M | $40.1M | +75.2% | +14.0% |
| May 7, 2026 | −$0.46 | −$0.37 | +19.6% | $21.4M | $18.7M | −12.9% | −13.6% |
| Mar 4, 2026 | −$0.49 | −$0.39 | +20.4% | $16.9M | $17.5M | +3.7% | +5.9% |
| Nov 4, 2025 | −$0.51 | −$1.35 | −164.7% | $16.5M | $11.2M | −32.0% | −20.1% |
| Aug 7, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 14, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 8, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 28, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 2, 2021 | |||||||
| May 11, 2021 | |||||||
| Mar 18, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 11, 2020 | |||||||
| Oct 29, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 12, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 13, 2018 | |||||||
| Nov 7, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 23, 2017 | |||||||
| Nov 7, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 9, 2016 | |||||||
| Mar 3, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 |